Denali Therapeutics (DNLI) Gains from Investment Securities (2017 - 2026)
Denali Therapeutics (DNLI) reported Gains from Investment Securities of -$294000.0 for Q1 2026, down 106.75% year-over-year from $4.4 million in Q1 2025, and up 96.71% on a QoQ basis from -$8.9 million in Q4 2025.
Denali Therapeutics (DNLI) has 10 years of Gains from Investment Securities data on file, last reported at -$294000.0 in Q1 2026.
- Quarterly Gains from Investment Securities fell 106.75% year-over-year to -$294000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.4 million (down 139.54% YoY) and the FY2025 annual result came in at -$772000.0, down 108.25% from the prior year.
- Gains from Investment Securities climbed to -$294000.0 in Q1 2026 per DNLI's latest filing, from -$8.9 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $11.2 million in Q3 2025 and bottomed at -$8.9 million in Q4 2025.
- The 5-year median for Gains from Investment Securities is $3500.0 (2023), against an average of $691250.0.
- The widest annual swing landed in 2024, when Gains from Investment Securities surged 272566.67%; it then sank 209.1% in 2025.
- Tracing DNLI's Gains from Investment Securities over 5 years: stood at $51000.0 in 2022, then tumbled by 94.12% to $3000.0 in 2023, then surged by 272566.67% to $8.2 million in 2024, then slumped by 209.1% to -$8.9 million in 2025, then soared by 96.71% to -$294000.0 in 2026.
- Per Business Quant, the three latest DNLI Gains from Investment Securities figures stand at -$294000.0 (Q1 2026), -$8.9 million (Q4 2025), and $11.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Denali Therapeutics | 3.82 Bn | 3.82 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -294,000.00 |
| Mar 31, 2026 | -294,000.00 |
| Dec 31, 2025 | -8.92 Mn |
| Dec 31, 2025 | -8.92 Mn |
| Sep 30, 2025 | 11.17 Mn |
| Sep 30, 2025 | 11.17 Mn |
| Jun 30, 2025 | -7.38 Mn |
| Jun 30, 2025 | -7.38 Mn |
| Mar 31, 2025 | 4.36 Mn |
| Mar 31, 2025 | 4.36 Mn |
| Dec 31, 2024 | 8.18 Mn |
| Dec 31, 2024 | 8.18 Mn |
| Sep 30, 2024 | 1.18 Mn |
| Sep 30, 2024 | 1.18 Mn |
| Dec 31, 2023 | 3,000.00 |
| Dec 31, 2023 | 3,000.00 |
| Sep 30, 2023 | -4,000.00 |
| Sep 30, 2023 | -4,000.00 |
| Mar 31, 2023 | 4,000.00 |
| Mar 31, 2023 | 4,000.00 |
| Dec 31, 2022 | 51,000.00 |
| Dec 31, 2022 | 51,000.00 |
| Sep 30, 2022 | -51,000.00 |
| Sep 30, 2022 | -51,000.00 |
| Jun 30, 2021 | -2,000.00 |
| Jun 30, 2021 | -2,000.00 |
| Mar 31, 2021 | 2,000.00 |
| Mar 31, 2021 | 2,000.00 |
| Dec 31, 2020 | -20,000.00 |
| Dec 31, 2020 | -20,000.00 |
| Sep 30, 2020 | -57,000.00 |
| Sep 30, 2020 | -57,000.00 |
| Jun 30, 2020 | -14,000.00 |
| Jun 30, 2020 | -14,000.00 |
| Mar 31, 2020 | 53,000.00 |
| Mar 31, 2020 | 53,000.00 |
| Sep 30, 2019 | 427,000.00 |
| Sep 30, 2019 | 427,000.00 |
| Jun 30, 2019 | 313,000.00 |
| Jun 30, 2019 | 313,000.00 |
| Dec 31, 2018 | 36,000.00 |
| Dec 31, 2018 | 36,000.00 |
| Jun 30, 2018 | -44,000.00 |
| Jun 30, 2018 | -44,000.00 |
| Mar 31, 2018 | 44,000.00 |
| Mar 31, 2018 | 44,000.00 |
| Sep 30, 2017 | -1,000.00 |
| Sep 30, 2017 | -1,000.00 |
| Jun 30, 2017 | -1.80 Mn |
| Jun 30, 2017 | -1.80 Mn |
| Mar 31, 2017 | 1.80 Mn |
| Mar 31, 2017 | 1.80 Mn |